Allogene Therapeutics is a pre-commercial allogeneic CAR-T biotech facing a critical liquidity crunch, with cash of $38.6M against a quarterly net loss of $42.7M, implying less than one quarter of runway absent financing. The company has narrowed operating los...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 12, 2026 | -$0.13+24.1% vs -$0.17 | $5M+185500.0% vs $2,500 |
Q2 2026 May 13, 2026 | -$0.18+5.3% vs -$0.19 | — vs $2,222 |
Q2 2026 Mar 12, 2026 | -$0.17+32.0% vs -$0.25 | — vs $2,500 |
Q4 2025 Nov 6, 2025 | -$0.19+17.4% vs -$0.23 | — vs $1,820 |
Bank of America Corp DE bought a new position in shares of Allogene Therapeutics, Inc. (NASDAQ: ALLO) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 3,187,320 shares of the company's stock, valued at approximately $6,630,000. Bank of America Corp
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?
Allogene Therapeutics, Inc. (ALLO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Frazier Life Sciences Management L.P. boosted its stake in shares of Allogene Therapeutics, Inc. (NASDAQ: ALLO) by 491.2% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,446,668 shares of the company's stock after acquiring an additional 18,650,000 shares during the quarter.
Benchmark ALLO against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Allogene Therapeutics, Inc. (ALLO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.50 | $517.73M | -1.72 | -100% | — | -53.42% | — | |
| $55.43 | $5.35B | -8.57 | -89.97% | -3368.72% | -24.39% | — | |
| $2.32 | $270.42M | -2.02 | -51.24% | -1941.09% | -65.08% | — | |
| $24.50 | $2.52B | -30.25 | 120.01% | -54.75% | -7.7% | — | |
| $12.26 | $1.38B | -3.22 | 16.92% | -672.16% | -57.79% | — | |
| $2.62 | $402.07M | -1.46 | 25.39% | -157.32% | -196.63% | — |
Allogene Therapeutics, Inc. (ALLO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Allogene Therapeutics, Inc. (ALLO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 12, 2026·SEC
Jun 22, 2026·SEC
May 28, 2026·SEC
Get notified when ALLO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Allogene Therapeutics, Inc. (ALLO) stock FAQ — growth, dividends, profitability & financials explained
Allogene Therapeutics, Inc. (ALLO) reported $4.6M in revenue for fiscal year 2025.
Allogene Therapeutics, Inc. (ALLO) saw revenue decline by 100.0% over the past year.
Allogene Therapeutics, Inc. (ALLO) reported a net loss of $165.5M for fiscal year 2025.
Allogene Therapeutics, Inc. (ALLO) has a return on equity (ROE) of -53.4%. Negative ROE indicates the company is unprofitable.
Allogene Therapeutics, Inc. (ALLO) had negative free cash flow of $102.6M in fiscal year 2025, likely due to heavy capital investments.
